Esperion Announces Closing of $225 Million Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil up about 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Esperion Therapeutics (ESPR) PT Lowered to $12 at Needham & Company, Keeps 'Buy' as Financing Extends Runway Into 2023
December 8, 2021 12:12 PM ESTNeedham & Company analyst Chad Messer lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $12.00 (from $20.00) while maintaining a Buy rating and says today's financing news addresses an overhang on the stock and extends the runway into 2023.
The analyst commented, "Last week,... More
